Global Blood Theraps Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for GLOBAL BLOOD THERAPS, and what generic alternatives to GLOBAL BLOOD THERAPS drugs are available?
GLOBAL BLOOD THERAPS has two approved drugs.
There are ten US patents protecting GLOBAL BLOOD THERAPS drugs.
There are two hundred and thirty-two patent family members on GLOBAL BLOOD THERAPS drugs in thirty-eight countries and seven supplementary protection certificates in seven countries.
Summary for Global Blood Theraps
| International Patents: | 232 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Global Blood Theraps
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | 11,020,382 | See Plans and Pricing | See Plans and Pricing | ||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | 10,017,491 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET, FOR SUSPENSION;ORAL | 216157-001 | Dec 17, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | RX | Yes | No | 10,493,035 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Global Blood Theraps | OXBRYTA | voxelotor | TABLET, FOR SUSPENSION;ORAL | 216157-001 | Dec 17, 2021 | RX | Yes | Yes | 10,017,491 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Global Blood Theraps Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Morocco | 43373 | See Plans and Pricing |
| Canada | 2902721 | See Plans and Pricing |
| New Zealand | 715029 | See Plans and Pricing |
| Brazil | 112015032160 | See Plans and Pricing |
| Netherlands | 301191 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Global Blood Theraps Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2797416 | 2022C/537 | Belgium | See Plans and Pricing | PRODUCT NAME: VOXELOTOR OU UN TAUTOMERE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/21/1622 20220215 |
| 2797416 | CA 2022 00032 | Denmark | See Plans and Pricing | PRODUCT NAME: VOXELOTOR ELLER EN TAUTOMER ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1622 20220215 |
| 2797416 | 122022000052 | Germany | See Plans and Pricing | PRODUCT NAME: VOXELOTOR ODER EIN TAUTOMER ODER PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1622 20220214 |
| 2797416 | 32/2022 | Austria | See Plans and Pricing | PRODUCT NAME: VOXELOTOR ODER EIN TAUTOMER ODER PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1622 (MITTEILUNG) 20220215 |
| 2797416 | 301191 | Netherlands | See Plans and Pricing | PRODUCT NAME: VOXELOTOR OF EEN TAUTOMEER OF FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1622 20220215 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
